Tau protein is involved in the apoptotic process induced by anti- microtubule agents on neuroblastoma cells

Apoptosis

Volumn 4, Issue 1, 1999, Pages 47-58

  Guise, S ^a   Braguer, D ^a   Remacle Bonnet, M ^a   Pommier, G ^a   Briand, C ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Anti microtubule agents; Apoptosis; Doxorubicin; Neuroblastoma; Tau; Taxoid

Indexed keywords

DOCETAXEL; DOXORUBICIN; NAVELBINE; PACLITAXEL; TAU PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CYTOPATHOGENIC EFFECT; DRUG EFFECT; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; MICROTUBULE; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0032794750     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009682116158     Document Type: Article

References (30)

1. Lee G, Cowan N, Kirschner M. The primary structure and heterogeneity of tau protein from mouse brain. Science 1988; 233: 285-288.
2. Johnson GV, Jenkins SM. Tau protein in normal and Alzheimer's disease brain. Alzheimers Dis Rev 1996; 1: 38-54.
3. Drubin DG, Kirschner MW. Tau protein function in living cells. J Cell Biol 1986; 103: 2739-2746.
4. Mandelkow EM, Mandelkow E. Tau as a marker for Alzheimer's disease. TIBS 1993; 18: 480-483.
5. Billingsley ML, Kincaid RL. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 1997; 323: 577-591.
6. AvilaJ, Dominguez J, Diaz-Nido J. Regulation of microtubule dynamics by microtubule-associated protein expression and phosphorylation during neuronal development. Int J Dev Biol 1994; 38: 13-25.
7. Garcia De Ancos J, Correas I, Avila J. Differences in microtubule binding and self association abilities of bovine brain tau isoforms. J Biol Chem 1993; 268: 7976-7982.
8. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991; 6: 487-498.
9. Mandelkow EM, Biernat J, Drewes G, Gustke N, Trinczek B, Mandelkow E. Tau domains, phosphorylation, and interactions with microtubules. Neurobiol Aging 1995; 16: 355-303.
10. Mills JC, Lee VMY, Pittman RN. Activation of a PP2A-like phosphatase and dephosphorylation of tau protein characterized onset of the execution phase of apoptosis. J Cell Sci 1998; 111: 625-636.
11. Tanaka T, Zhong J, Iqbal K, Trenkner E, Grundke-Iqbal I. The regulation of phosphorylation of τ in SY5Y neuroblastoma cells: the role of protein phosphatases. FEBS Lett 1998; 426: 248-254.
12. Uberti D, Rizzini C, Spano P, Memo M. Characterization of tau proteins in human neuroblastoma SH-SY5Y cell line. Neurosci Lett 1997; 235: 149-153.
13. Han-Qing X, Johnson GV Ceramide selectively decreases tau levels in differentiated PC12 cells though modulation of calpain I. J Neurochem 1997; 69: 1020-1030.
14. Garcia P, Braguer D, Carles G, et al. Comparative effects of taxol and taxotere on two different human carcinoma cell lines. Cancer Chemother Pharmacol 1994; 4: 335-343.
15. Carles G, Braguer D, Sabeur G, Briand C. The effect of combining anti-tubulin agents on differentiated and undifferentiated human colon cancer cells. Anti-Cancer Drugs 1998; 9: 209-221.
16. Debal V, Allam N, Morjani H, et al. Characterization of a navelbin-resistant bladder carcinoma cell line cross-resistant to taxoids. Br J Cancer 1994; 70: 1118-1125.
17. De Ines C, Leynadier D, Barasoain I, et al. Inhibition of microtubules and cell cycle arrest by a new I-deaza-7, 8-dihydroptendine antitumor drug, and by its chiral isomer, NSC 613863. Cancer Res 1994; 54: 75-84.
18. Garcia P, Braguer D, Carles G, Briand C. Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses. Anti-Cancer Drugs 1995; 6: 533-544.
19. Van Engeland M, Ramackers FC, Schutte B, Reutelingsperger CP. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 1996; 24: 131-139.
20. Remacle-Bonnet MM, Garrouste FL, Pommier GJ. Surface-bound plasmin induces selective proteolysis of Insulin-like-Growth-Factor (IGF)-Binding Protein-4 (IGFBP-4) and promotes autocrine IGF-II bio-availability in human colon-carcinoma cells. Int J Cancer 1997; 72: 835-843.
21. Lasorella A, Iavarone A, Israel MA. Differentiation of neuroblastoma enhances bcl-2 expression and induces alterations of apoptosis and drug resistance. Cancer Res 1995; 55: 4711-4716.
22. Babajko S, Binoux M. Modulation by retinoic acid of insulin-like growth factor (IGF) and IGF binding protein expression in human SK-N-SN neuroblastoma cells. Eur J Endocrinol 1996; 134: 474-480.
23. Cianfarani S, Germani D, Rossi P, Spagnoli A, Mercanti D. Do insulin-like growth factor binding proteins (IGFBPs) modulate the IGF-I growth promoting and differentiating effects in human neuroblastoma cells? Eur J Endocrinol 1996; 135: 716-723.
24. Hossenlopp P, Segovia B, Lassare C, Roghani M, Bredon M, Binoux M. Evidence of enzymatic degradation of insulin-like growth factor binding proteins in the 150 kD complex during pregnancy. J Clin Endocrinol Metab 1990; 71: 797-805.
25. Tishler RB, Lamppu DM, Park S, Price BD. Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res 1995; 55: 6021-6025.
26. Debernardis D, Graniela Sire E, De Feudis P, et al. p53 status does not affect sensitivity of human ovarian cancer cell lines. Cancer Res 1997; 57: 870-874.
27. Ponzoni M, Bocca P, Chiesa V, et al. Differential effects of N-(4-Hydroxyphenyl) retinamide and retinoic acid on neuroblastoma cells: Apoptosis versus differentiation. Cancer Res 1995; 55: 853-861.
28. Nuydens R, Heers C, Chadarevian A, et al. Sodium butyrate induces aberrant tau phosphorylation and programmed cell death in human neuroblastoma cells. Brain Res 1995; 688: 86-94.
29. Vulliet R, Halloran SM, Braun R, Smith A, Lee G. Proline-directed phosphorylation of human tau protein. J Biol Chem 1992; 267: 22570-22574.
30. Drewes G, Lichten-Kraag B, Doring F, et al. Mitogen-activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J 1992; 11: 2131-2138.